Lavoltidine

Lavoltidine
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	Development terminated;
Identifiers
	IUPAC name [1-methyl-5-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]-1,2,4-triazol-3-yl]methanol;
CAS Number	76956-02-0;
PubChem CID	55473;
ChemSpider	50093;
UNII	X16K5179V5;
CompTox Dashboard (EPA)	DTXSID0020785 ;
Chemical and physical data
Formula	C19H29N5O2
Molar mass	359.474 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES OCc1nn(C)c(n1)NCCCOc2cccc(c2)CN3CCCCC3;

Lavoltidine (INN,^[1] USAN, BAN; previously known as loxtidine; development code AH-23,844) is a highly potent and selective H₂ receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline)^[2] as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.^[3]^[4]

Quick facts Clinical data, Routes ofadministration ...

See also